The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Index Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -4.18% | -0.29% | 13.6% | 15.38% | 14.48% | 4.32% | 18.13% | N/A | N/A | N/A | 18.71% |
| Category returns | -3.49% | -4.55% | -2.01% | -3.44% | -4% | -2.79% | 10.35% | 12.84% | 9.89% | 11.18% | N/A |
| Absolute returns | -4.18% | -0.29% | 13.6% | 15.38% | 14.48% | 8.83% | 64.9% | N/A | N/A | N/A | 93.51% |
| Rank within category | 112/216 | 16/207 | 2/199 | 6/193 | 3/184 | 8/116 | 3/65 | N/A | N/A | N/A | N/A |
| Index Funds | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Yearly returns | N/A | 31.93% | 37.98% | -3.17% | 12.34% |
| Q1 returns | N/A | -4.58% | 12.7% | -9.66% | -2.23% |
| Q2 returns | N/A | 13.7% | 3.45% | 4.15% | 13.7% |
| Q3 returns | N/A | 11.86% | 18.06% | -2.6% | 4.36% |
| Q4 returns | N/A | 8.7% | 0.25% | 5.66% | -3.17% |
Nil
| Alpha | -0.0985431 |
| Beta | 0.9941 |
| Sharpe Ratio | 0.285323 |
| Sortino Ratio | 0.619353 |
| R-Squared | 0.9968 |
| Tracking Error | 0.089 |
| Downside Risk | 16.6201 |
| Std. Deviation (Annualised) | 13.8534 |
| Index Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICICI Prudential NASDAQ 100 Index Fund - Growth | -1.52% | 1.37% | 12.73% | 20.33% | 27.46% | 30.85% | 18.72% | N/A | 18.87% | 3,738.17 | 1.06 | 0.39 | Very High |
| Motilal Oswal S&P 500 Index Fund - Regular Plan - Growth | -0.5% | 1.6% | 10.19% | 15.5% | 24.15% | 26.62% | 16.54% | N/A | 19.94% | 4,584.30 | 1.04 | 0.44 | Very High |
| ICICI Prudential Nifty Pharma Index Fund - Regular Plan - Growth Current | -4.18% | -0.29% | 13.6% | 15.38% | 14.48% | 18.13% | N/A | N/A | 18.71% | 163.10 | 1.18 | 0.29 | Very High |
| UTI Nifty 500 Value 50 Index Fund - Regular Plan - Growth | -4.93% | -6.29% | -9.73% | -4.85% | 2.97% | 18.1% | N/A | N/A | 23.08% | 838.01 | 1.21 | 0.21 | Very High |
| Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund - Regular Plan - Growth | -4.3% | -1.59% | 11.56% | 11.09% | 13.2% | 17.83% | 12.7% | N/A | 14.93% | 191.85 | 1.10 | 0.32 | Very High |
| Motilal Oswal BSE Enhanced Value Index Fund - Regular Plan - Growth | -3.42% | -6.2% | -9.67% | -9.99% | -0.86% | 17.49% | N/A | N/A | 24.9% | 2,131.66 | 1.12 | 0.19 | Very High |
| Aditya Birla Sun Life Nifty Smallcap 50 Index Fund - Regular Plan - Growth | -4.83% | -1.02% | 10.76% | 12.27% | 8.48% | 15.62% | 10.2% | N/A | 15.72% | 364.19 | 1.11 | 0.18 | Very High |
| Kotak Nifty Smallcap 50 Index Fund - Regular Plan - Growth | -5.01% | -1.19% | 10.63% | 11.86% | 8.08% | 15.42% | N/A | N/A | 24.48% | 259.53 | 0.92 | 0.18 | Very High |
| ICICI Prudential Nifty Auto Index Fund - Regular Plan - Growth | -5.75% | -5.5% | -2.85% | -7.06% | -5.92% | 15.29% | N/A | N/A | 19.15% | 234.49 | 0.95 | 0.18 | Very High |
| Axis Nifty Smallcap 50 Index Fund - Regular Plan - Growth | -4.83% | -1.05% | 10.71% | 12.17% | 8.37% | 15.25% | N/A | N/A | 15.6% | 777.66 | 1.13 | 0.17 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 19.50% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 11.97% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.82% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.68% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.62% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.16% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.00% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.68% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.56% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.16% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.92% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.88% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.71% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.62% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.34% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.14% |
| Wockhardt Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.77% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.67% |
| TREPS | Cash & Cash Equivalents and Net Assets | 1.50% | |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.43% |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.30% |
| Net Current Assets | Cash & Cash Equivalents and Net Assets | -1.44% | |
| Total | 100.00% | ||
Mr. Nishit Patel joined ICICI Prudential Asset Management Company Limited in November 2018.
Ms. Ashwini was appointed as the Deputy Manager - Dealer Support in the Investment Department of ICICI Prudential Asset Management Company Ltd. w.e.f. August 1, 2024. During November 2024, she was appointed as fund manager for certain passive schemes.
Mr. Venus Ahuja was appointed as dealer in the Investments Department of ICICI Prudential Asset AMC.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
